Borui Medicine opened the daily limit today (January 21) because it was approved to imitate Merck’s new crown oral drug.
On January 20, MPP, a drug patent pool organization, announced an agreement with 27 generic drug manufacturers to supply Merck’s new crown oral drug Molnupiravir to 105 low- and middle-income countries around the world. Among the 27 companies, 5 are from China, and Borui Pharmaceutical is one of them. Borui Pharmaceutical has obtained a free license to produce both Molnupiravir APIs and finished drugs.
Regarding the follow-up production capacity planning and the above-mentioned market entry and other issues, the staff of Borui Pharmaceutical Securities Department said, “Everything is subject to the announcement and disclosure.”
Molnupiravir is an oral ribonucleoside analog under development that inhibits the replication of SARS-CoV-2, the causative agent of the new coronavirus, jointly developed by Merck & Co and Ridgeback.
Earlier, clinical data disclosed by Merck showed that Molnupiravir can reduce the risk of hospitalization and death by 50%. But later data showed that Molnupiravir was only 30% effective at reducing Covid-19 hospitalizations and deaths, far less than the 89% effectiveness of Pfizer’s Covid-19 oral drug Paxlovid.
In addition, it is worth noting that the above 105 markets do not include major markets such as China and Brazil. Although the above 105 countries cover half of the world’s population, they have poor affordability and a small market share of drugs. Some market analysts believe that the authorization has little impact on Merck’s new crown oral drug sales, and whether Borui Medicine can seize the opportunity still needs to consider a lot of factors.
[If you want to know more financial information, click to download the Hexun Finance APP, which is used by 15 million financial experts]Return to Sohu, see more
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.